ScholarLens Back to search
2019•IJU Case ReportsOpen access

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer

Yoshinori Yanai, Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya

Open full text 1 citations

Abstract

INTRODUCTION: Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration-resistant prostate cancer. CASE PRESENTATION: A 62-year-old patient with a bone metastatic castration-resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg a day along with 10 mg prednisone. In spite of castrate testosterone level, the laboratory test showed a relatively high level of serum testosterone, which was 21 ng/dL. Within 6 months, the patient achieved a complete prostate-specific antigen response. Follow-up bone scintigraphy demonstrated no area of intense uptake. He had a history of hyperlipidemia and was started on atorvastatin at home just after starting abiraterone acetate. CONCLUSION: This report is a rare case of a clinically complete response to abiraterone acetate in a patient with metastatic castration-resistant prostate cancer.

Open-access reader

About this research paper

What this paper is about

INTRODUCTION: Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration-resistant prostate cancer. CASE PRESENTATION: A 62-year-old patient with a bone metastatic castration-resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg a day along with 10 mg prednisone. In spite of castrate testosterone level, the laboratory test showed a relatively high level of serum testosterone, which was 21 ng/dL. Within 6 months, the patient achieved a complete prostate-specific antigen response. Follow-up bone scintigraphy demonstrated no area of intense uptake. He had a history of hyperlipidemia and was started on atorvastatin at home just after starting abiraterone acetate. CONCLUSION: This report is a rare case of a clinically complete response to abiraterone acetate in a patient with metastatic castration-resistant prostate cancer.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

INTRODUCTION: Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration-resistant prostate cancer. CASE PRESENTATION: A 62-year-old patient with a bone metastatic castration-resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg a day along with 10 mg prednisone. In spite of castrate testosterone level, the laboratory test showed a relatively high level of serum testosterone, which was 21 ng/dL. Within 6 months, the patient achieved a complete prostate-specific antigen response. Follow-up bone scintigraphy demonstrated no area of intense uptake. He had a history of hyperlipidemia and was started on atorvastatin at home just after starting abiraterone acetate. CONCLUSION: This report is a rare case of a clinically complete response to abiraterone acetate in a patient with metastatic castration-resistant prostate cancer.

Key concepts: Abiraterone acetate, Prostate cancer, Medicine, Castration, Prednisone, Urology, Testosterone (patch), Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer — Research Paper | ScholarLens